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Context: More than half of unilateral primary aldosteronism (UPA) suffer from persisting 
hypertension after unilateral adrenalectomy.  
Objective: To develop and validate a nomogram-based preoperative score (NBPS) for 
prediction clinical outcome for UPA.  
Design and setting: The NBPS were developed in an Asian cohort by incorporating 
predictors independently associated with hypertension remission in UPA patients in the 
multivariate analyses and validated in a Caucasian cohort.  
Participants: UPA achieving complete biochemical success after unilateral adrenalectomy. 
Main outcome measure: the predictive performance of NBPS compared with two previously 
developed outcome prediction scores: aldosteronoma resolution score (ARS) and primary 
aldosteronism surgical outcome (PASO) score. 
Results: Ninety-seven of 150(64.7%) patients achieved complete clinical success after 
unilateral adrenalectomy in the training cohort and 57 out of 165(34.5%) in the validation 
cohort. A nomogram was established by incorporating sex, duration of hypertension, 
aldosterone to renin ratio and target organ damage. The nomogram achieved good 
concordance indexes and calibration curve in both cohorts. The area under the receiver 
operating characteristic curve (AUC) of NBPS for predicting hypertension remission in the 
training cohort was 0.853(0.786-0.905), which was superior to ARS [0.745(0.667-0.812), 
p=0.019] and PASO score [0.747(0.670-0.815), p=0.012]. The AUC of NBPS in the 
validation cohort was 0.830 (0.764-0.884), which was higher than ARS [0.745 (95% CI 
0.672-0.810), p=0.045], but not significantly different from PASO score [0.825 (95% CI 
0.758-0.880), p=0.911].  
Conclusion: The NBPS is useful in predicting clinical outcome for UPA patients, especially 
in the Asian population. 
Precis: we developed a novel outcome prediction score based upon sex, duration of 
hypertension, aldosterone to renin ratio and target organ damage to allow estimating the 
clinical outcome for UPA patients. 
 




























Primary aldosteronism (PA) is the most common cause of endocrine hypertension, with a 
prevalence of nearly 5-10% in the general hypertensive population and as high as 20% in 
resistant hypertensives (1-4). The inappropriate elevation of plasma aldosterone concentration 
predisposes PA patients to an increased risk of cardiovascular, cerebrovascular and renal 
complications when compared with age-, gender- and blood pressure-matched patients with 
essential hypertension (5,6). PA is typically classified into unilateral and bilateral subtypes, 
with unilateral PA (UPA) consisting of aldosterone-producing adenoma (APA) and unilateral 
adrenal hyperplasia. UPA can be cured biochemically, with complete resolution of the 
hyperaldosteronism after unilateral adrenalectomy. As for postoperative blood pressure, 
nearly half of patients with UPA suffer from persisting hypertension (7-9). According to the 
Primary Aldosteronism Surgical Outcome (PASO) study, only 37% (17%-63%) of patients 
with UPA achieved complete clinical success after unilateral adrenalectomy, defined as 
normalization of blood pressure without any anti-hypertensive drugs (10). Thus, for clinicians 
and patients to have realistic expectations of clinical outcomes, it is crucial for them to be 
aware of predictors of complete clinical success before they undergo surgery.   
It has previously been reported that sex, duration of hypertension and body mass index 
(BMI) are preoperative predictors of clinical outcome after unilateral adrenalectomy for UPA 
(11-15). To utilize these parameters in clinical practice, an Aldosteronoma Resolution Score 
(ARS) was established (16), which incorporated sex, duration of hypertension, number of 
preoperative antihypertensive drugs and BMI in a points system to predict three levels (low, 
medium, high) of likelihood of complete clinical success. The ARS performed well in an 
American cohort (17) and a Japanese cohort (18) but not in a French cohort (19). Utsumi T et 
al. also used a nomogram to estimate hypertension remission in UPA by incorporating age, 
female sex, duration of hypertension and number of anti-hypertensive drugs (20), although 
this normogram was only tested in a Japanese cohort. Recently, a Primary Aldosteronism 
Surgical Outcome (PASO) score was also developed (21) using clinical data from 8 different 
international centers, which additionally employed target organ damage (TOD) and adrenal 
nodule size on imaging as predictive factors. However, these predictive scores did not use 
certain pivotal clinical and biochemical predictors of hypertension remission in UPA. It was 
recently reported that the plasma aldosterone concentration (PAC) post saline infusion test 
(SIT) (22) and medical history of diabetes (23) can predict hypertension remission in UPA. 
Additionally, the aldosterone to renin ratio (ARR) is also associated with hypertension 
remission in UPA, although the association only existed in univariate analysis (24). 
The present study is an international multi-center, multi-ethnic study, which 
comprehensively evaluated potential clinical and biochemical predictors of hypertension 
remission in UPA by stepwise selection. The selected predictors were incorporated into a 
novel user-friendly nomogram-based preoperative score (NBPS). We also compared the 




















Patient data were collected from 3 international hypertension referral centers between 
April 6, 2014, and February 22, 2020 [Chongqing China (n=163), Munich Germany (n=98), 
Torino Italy (n=75). The Chongqing cohort (Chinese) was used as the training cohort and the 
Munich/Torino cohort (European) are a subset of patients from the PASO study (10) and were 
used as the validation cohort. Ethics approval was given by local ethics committees in all 
centers and written informed consent was acquired from all participants enrolled. The 
criterion for inclusion were: 1: confirmed diagnosis of UPA according to the Endocrine 
Society guideline (25), and as described below; 2: post-surgical follow-up for at least 6 
months. The criterion for exclusion were: 1: patients with UPA who failed to achieve 
complete biochemical success after unilateral adrenalectomy; 2: with a post-surgical 
follow-up shorter than 6 months. 
Diagnosis of PA and UPA 
The diagnosis of PA was achieved in accordance with the Endocrine Society guidelines 
(25), consisting of case detection, confirmatory testing and subtype classification. All 
antihypertensive drugs interfering with case detection were stopped at least 2 weeks before 
screening (at least 4 weeks for diuretics). At least one diagnostic confirmation test of saline 
infusion testing or captopril challenge testing was used according to local protocols. In the 
training cohort, UPA was identified by: (1) adrenal venous sampling in 132 patients, or (2) 
typical adenoma on computed tomography (CT) scanning and age35 years old, as described 
previously (26-28), in 18 patients. In the validation cohort, UPA was confirmed by adrenal 
venous sampling in all patients. Criteria for case detection, confirmation tests and AVS 
interpretation were described in the Supplementary Materials (29). 
   
Laboratory measurements 
In the Chongqing and Munich cohort, direct renin concentrations (DRC, mU/liter) and 
plasma aldosterone concentrations (PAC, pg/ml) were measured using an automated 
chemiluminescence immunoassay (LIAISON; DiaSorin, Italy). In the Torino cohort, plasma 
aldosterone concentration (PAC, pg/ml) was assessed by solid-phase radioimmunoassay 
ALDOCTK-2 (DiaSorin, Saluggia, Italy) and plasma renin activity (PRA, ng/ml/h) was 
assessed using the RENCTK RIA kit (DiaSorin). For the calculation of the aldosterone to 
renin ratio (ARR), PRA was converted to DRC using the conversion factor of 8.2 (1ng/mL/hr 
PRA = 8.2 mU/L DRC) based upon the Endocrine Society guideline (25). 
Definition of Target organ damage, medical history of diabetes and hypokalemia.  
Target organ damage was defined according to the guidelines of the European Society of 
Hypertension (30), namely presence of left ventricular hypertrophy and/or microalbuminuria. 
Left ventricular hypertrophy was assessed by electrocardiography and/or echocardiography. 
Left ventricular hypertrophy assessed by electrocardiography was defined as a Sokolow–Lyon 
index >3.5 mV; left ventricular hypertrophy assessed by echocardiography was defined as a 
left ventricular mass index >115 g/m2 for men and >95 g/m2 for women; microalbuminuria 
was defined as a 24 h urinary albumin between 30–300 mg or by an albumin to creatinine 
ratio of 30–300 mg/g. In the training cohort, all the results for LVH were determined by 
echocardiography. In the validation cohort, LVH were determined by echocardiography in XX 
patients (the specify number of patients with electrocardiography/ electrocardiography in 
Torino and Munich is required). Medical history of diabetes was defined according to the 
2015 American Diabetes Association criteria (31) as a fasting plasma glucose level greater 
than 7.8 mmol/L and/or a postprandial 2h plasma glucose level greater than 11.1 mmol/L. 
Hypokalemia was defined as serum concentration of potassium lower than 3.5 mmol/L. 
Definition of biochemical outcome and clinical outcome 
Biochemical and clinical outcomes were classified as complete, partial, or absent 
success and were defined according to the PASO criteria (10).   
Blood pressure measurement 
In both cohorts, blood pressure of UPA patients were measured in the office, as refer to 
European Society of Hypertension/European Society of Cardiology guidelines for the 
management of arterial hypertension (32,33). The detail methods were previously described 
(26,34) and is available in the Supplementary Materials (29).  
Development and validation of the nomogram and the nomogram-based predictive score 
Univariate and multivariate logistic regression analysis were used to identify predictors 
of hypertension remission in UPA. A nomogram was formulated based on the results of 
multivariate logistic regression analysis and by using the rms and forign package of R, 
version 3.6.1 (http://www.r-project.org/). The nomogram was established by proportionally 
converting each regression coefficient in the multivariate logistic regression to a 0- to 
100-point scale. The variable with the highest β coefficient (absolute value) was assigned 100 
points. The predictive performance of the nomogram was evaluated by concordance index (C 
index) and calibrated by the bootstrap method, the higher a C index of a nomogram, the better 
a predictive performance it would achieve (35,36). A nomogram-based predictive score 
(NBPS) was established. In the NBPS, the continuous variables, were firstly categorized into 
low, medium or high levels based on data from the entire cohort with the cut-offs of each 
category determined by tertiles,) and all the variables were weighted according to its weight 
in the nomogram. 
Statistical Analysis 
Data distributions were analyzed by Kolmogorov-Smirnov test. Normally distributed 
variables were expressed as mean ± standard deviation (SD) and were analyzed by the student 
t test. Skewed distributed variables were expressed as median (quartile range) and analyzed 
after a Z logarithm transformation. Categorical variables (sex, target organ damage) were 
expressed as absolute numbers and proportions (%) and analyzed by a chi-square test. All 
variables significantly associated with hypertension remission were candidates for stepwise 
multivariate analysis (forward). All above analyses were performed using SPSS (version 
21.0). Receiver operating characteristic (ROC) curve analysis was used to calculate the 
predictive performance of the NBPS, ARS, PASO score and the nomogram established by the 
Japanese team and were performed using MedCalc software 8.1.1.0. In all analyses, p< 0.05 
was considered statistically significant. 
Results 
A total of 315 cases of UPA with post-surgical complete biochemical success were 
enrolled in the present study, with the training cohort comprising 150 cases and the validation 
cohort comprising 165 cases (Figure 1).  
Ninety-seven out of 150 cases (64.7%) achieved complete clinical success after 
unilateral adrenalectomy in the training cohort after at least 6 months of post-surgical 
follow-up. In the training cohort, patients with complete clinical success were younger 
(43.6±12.8 vs. 48.9±10.6, p=0.011), more frequently female (78.4% vs. 43.4%, p<0.001), had 
a shorter duration of hypertension [3.0 (1.0, 8.0) vs. 8.0 (3.0, 13.5), p=0.001] and a lower BMI 
(22.7±2.7 vs. 24.8±3.5, p<0.001) compared with patients in the partial plus absent clinical 
success group. Patients with complete clinical success also had a lower systolic blood 
pressure (153.4±17.6 vs. 160.7±17.4, p=0.016), a higher pre-operative ARR [293.5 (95.8, 
487.1) vs. 89.8 (43.1, 195.4), p<0.001], a higher PAC post-SIT [288.0 (180.5, 465.0) vs. 208.0 
(133.0, 308.0), p=0.013] and a lower incidence of medical history of diabetes (8.2% vs. 28.3%, 
p=0.002). As for target organ damage (TOD), the prevalence of left ventricular hypertrophy 
(LVH) was lower in those with post-surgical complete clinical success (40.2% vs 77.4%, 
p<0.001), but the incidence of microalbuminuria was not significantly different between the 
two groups (47.9% vs 57.1%, p=0.483). The overall prevalence of TOD was lower in those 
with post-surgical complete clinical success (56.7% vs. 86.8%, p<0.001). The prevalence of 
family history of hypertension, the defined daily dose (DDD) of anti-hypertensive drugs and 
the largest adrenal nodule size at imaging were not significantly different between the two 
groups (Table 1).  
In the validation cohort, 57 of 165 cases (34.5%) achieved complete clinical success 
after unilateral adrenalectomy after at least 6 months of post-surgical follow-up. In line with 
the training cohort, UPA patients with complete clinical success in the validation cohort were 
also younger (44.9±10.4 vs. 52.9±10.3, p<0.001), more frequently female (64.9% vs. 32.4%, 
p<0.001), had a shorter duration of hypertension [5.1 (1.3, 7.6) vs. 8.0 (3.0, 13.5), p<0.001] 
and a lower BMI (25.0±4.3 vs. 28.3±4.5, p<0.001) compared with patients with partial plus 
absent clinical success. Patients with complete clinical success in the validation cohort also 
had a lower systolic blood pressure (155.2±20.9 vs. 164.8±26.2, p=0.019) and a higher 
pre-operative ARR [178.3 (84.2, 291.0) vs. 56.3 (15.0, 145.5), p<0.001]. As for TOD, the 
prevalence of LVH was lower in those with post-surgical complete clinical success (42.1% vs 
71.3%, p<0.001), but the incidence of microalbuminuria was not significantly different 
between the two groups (34.0% vs 41.7%, p=0.483). The overall prevalence of TOD was 
lower in those with post-surgical complete clinical success (50.9% vs. 81.5%, p<0.001). In 
contrast to the training cohort, UPA patients with complete clinical success in the validation 
cohort had a lower defined daily dose (DDD) of anti-hypertensive drugs [2.1 (1.5, 4.2) vs. 4.0 
(2.0, 5.6), p=0.001] and a larger nodule size at imaging [15.1 (10.0, 21.5) vs. 14.0 (9.0, 16.7), 
p=0.014] compared with the partial plus absent clinical success group (Supplemental Table 
1)(29).   
We also compare the clinical and biochemical parameters between the training cohort 
and the validation cohort. UPA patients in the training cohort were more frequently female 
(66.0% vs. 43.6%, p<0.001), had a higher incidence of complete clinical success (64.7% vs. 
34.5%, p<0.001) and a higher ARR [201.6 (56.6, 445.6) vs. 87.4 (27.8, 219.2), p<0.001]. In 
addition, UPA patients in the training cohort were younger (45.5±12.3 vs. 50.2±11.0, p<0.001), 
had a lower duration of hypertension [4.0 (1.0, 10.0) vs. 7.4 (3.2, 14.6), p<0.001)], a lower 
BMI (23.5±3.2 vs. 27.2±4.8, p<0.001), a lower systolic blood pressure (156.0±17.9 vs. 
161.5±24.9, p=0.026), a lower DDD of anti-hypertensive medication [2.0 (1.0, 2.7) vs. 3.3 
(2.0, 5.0), p<0.001)] (Supplemental Table 2)(29). 
     Univariate and multivariate logistic regression analysis were used to identify predictors 
of hypertension remission in UPA in the training cohort. univariate analysis showed that age 
[OR, 0.964 (95% CI, 0.937-0.992), p=0.012], duration of hypertension [OR, 0.938 (95% CI, 
0.891-0.986), p=0.012], female sex [OR, 4.720 (95% CI, 2.282-9.766), p<0.001], BMI [OR, 
0.794 (95% CI, 0.705-0.895), p<0.001], systolic blood pressure [OR, 0.977 (95% CI, 
0.958-0.996), p=0.018], ARR [OR, 1.788 (95% CI, 1.328-2.407), p<0.001], PAC post-SIT 
[OR, 1.723 (95% CI, 1.154-2.574), p=0.008], absence of medical history of diabetes [OR, 
0.228 (95% CI, 0.089-0.582), p=0.002] and absence of TOD [OR, 0.199 (95% CI, 
0.082-0.486), p<0.001] were associated with complete clinical success in UPA (Table 2). All 
variables significantly associated with hypertension remission (P<0.05) in the univariate 
analysis were candidates for stepwise multivariate analysis (forward). Four variables were 
independent predictors of complete clinical success in the multivariate analysis (Table 3). 
Female sex was the strongest independent predictor [OR, 5.374 (95% CI, 2.257-12.792), 
p<0.001], followed by ARR [OR, 2.183 (95% CI, 1.503-3.169), p<0.001], and duration of 
hypertension [OR, 0.910 (95% CI, 0.854-0.970), p=0.004] and absence of TOD [OR, 0.278 
(95% CI, 0.099-0.783), p=0.015]. 
     A nomogram was established by incorporating the four significant parameters from the 
multivariate analysis (sex, ARR, duration of hypertension and TOD) (Figure 2A). The 
nomogram demonstrated a good accuracy in predicting hypertension remission in UPA, with 
a bootstrap-corrected C-index of 0.842 (95% CI, 0.774-0.897). In addition, calibration plots 
showed good agreement between the actual status of hypertension remission and the 
probability of hypertension remission estimated by the nomogram (Figure 2B). In the 
validation cohort, the nomogram also displayed a well C-index of 0.833 (95% CI, 0.767-0.886) 
for the prediction of hypertension remission in UPA and a good agreement in the calibration 
plots (Figure 2C). 
To facilitate routine clinical use, a nomogram-based predictive score (NBPS) was 
established. In the model of NBPS, four predictors were weighted according to their weight in 
the nomogram. Categorical variables of sex and TOD were weighted 3.5 (for female) and 2.5 
(for absence of TOD) points, respectively. The continuous variables, ARR and duration of 
hypertension, were categorized into low, medium or high levels according to the nomogram. 
In the NBPS, low, medium or high levels of ARR (pg.ml-1/mIU.l-1) were defined as ≤60, 
60.1-180 or 180 and were weighted 0, 5, 10 points, respectively. The duration of 
hypertension (years) was categorized as ≤5, 5.1-10, 10 and weighted 6, 3, 0 points, 
respectively (Table 4). 
We then compared the predictive performance of NBPS to the previously established 
ARS and PASO score in predicting hypertension remission in UPA. The ARS and PASO score 
of all UPA patients were calculated as previously described (16,21). In the training cohort, 
compared with those without complete clinical success (partial plus absent clinical success), 
patients with complete clinical success had a higher ARS and PASO score [4.0 (3.0-5.0) vs. 
3.0 (2.0-4.0), p<0.001] and [19.0 (16.0-21.0) vs. 15.0 (12.5-17.0), p<0.001], respectively. The 
NBPS in patients with complete clinical success was also significantly higher than the partial 
plus absent clinical success group [16.5 (13.5-19.5) vs. 8.5 (6.0-12.5), p<0.001]. In the 
validation cohort, those with complete clinical success also had a higher ARS and PASO 
score compared with those in the partial plus absent complete clinical success group [3.00 
(2.00-4.50) vs. 1.00 (0.00-2.00), p<0.001] and [18.00 (14.50, 21.75) vs. 12.00 (9.13, 14.38), 
p<0.001], respectively. The NBPS in patients with complete clinical success was also 
significantly higher than the partial plus absent clinical success group [14.5 (10.5-17.0) vs. 6.0 
(3.5-10.5), p<0.001] (Supplemental Table 3) (29). In the training cohort, ROC curve analysis 
revealed that NBPS could accurately predict hypertension remission in UPA, with an area 
under ROC curve (AUC) of 0.853(0.786-0.905), which was superior to that of ARS 
[0.745(95% CI 0.667-0.812), p=0.019] and PASO score [0.747(95% CI 0.670-0.815), 
p=0.012] (Figure 3A). In the validation cohort, the AUC of NBPS was 0.830 (0.764-0.884), 
which was superior to that of ARS [0.745 (95% CI, 0.672-0.810), p=0.045], but not 
significantly different from the PASO score [0.825 (95% CI, 0.758-0.880), p=0.911] (Figure 
3B). We also compared our NBPS to the nomogram established by the Japanese team (20), 
and found that the AUC of the NBPS is superior to that of the nomogram developed by the 
Japanese team in the training cohort [0.853 (0.786-0.905) vs. 0.731 (95% CI, 0.653-0.800), 
p=0.005], though no significant difference was found in the validation cohort [0.830 
(0.764-0.884) vs. 0.770 (95% CI, 0.698-0.832), p=0.157] (Supplemental Figure 1)(29). 
The optimal cut-off of NBPS for the prediction of hypertension remission was 11.5, 
with a sensitivity of 85.6% (77.0%-91.9%) and a specificity of 71.7% (57.7%-83.2%) in the 
training cohort and a sensitivity of 68.4% (54.8%-80.1%) and a specificity of 78.7% 
(69.8%-86.0%) in the validation cohort (Table 5). If we use a cut-off of NBPS≥16.5, the 
specificity of NBPS is increased to 94.3%; while usingNBPS≥8.5, the sensitivity of NBPS is 
increased to 95.9% (Supplemental Table 4) (29). 
Discussion 
In the present study, we found the ARR to be a robust predictor of hypertension 
remission in UPA patients and established a nomogram-based preoperative score (NBPS) for 
the prediction of clinical outcome for UPA patients in a large international multi-ethnic cohort. 
Our newly developed NBPS was useful in predicting hypertension remission for UPA patients 
following adrenal surgery, especially in Asian patients.  
     Efforts have been made to establish an outcome-prediction model (16,21) in UPA. Both 
ARS and PASO score performed well in predicting the likelihood of hypertension remission 
following the surgical treatment of UPA. However, these scores did not incorporate several 
recently reported predictors of hypertension remission (22,23) whereas the present study 
comprehensively evaluated all the relevant clinical and biochemical parameters. Consistent 
with the previously developed ARS and PASO score, our NBPS presented herein also 
employed female sex, duration of hypertension and absence of TOD as predictors of 
hypertension remission in UPA. However, BMI was excluded because its correlation with 
hypertension remission only appeared in the univariate analysis. Additionally, the 
preoperative number of anti-hypertensive drugs (DDD) and adrenal nodule size were also 
excluded because these variables were not significantly different between those with complete 
clinical success and those without. The difference in parameters between NBPS and PASO 
score could be attributed to the relatively lower predictive performance of BMI and adrenal 
nodule size, as shown by the borderline odds ratio in the study of PASO score (21). The DDD 
of anti-hypertensive drugs was excluded because its association with hypertension remission 
may be directly related to the duration of hypertension and ARR. 
Besides three abovementioned clinical characteristics, we also found the ARR to be a 
robust predictor of hypertension remission in UPA patients. The difference in ARR between 
training and validation cohorts (201.6 vs 87.4) could be partially attributed to referral bias, as 
there is a lower level of awareness of PA case detection in China compared to Japan and Italy, 
so the majority of PA patients has a more pronounced hyperaldosteronism in the hypertension 
referral center in China. The role of the ARR in predicting hypertension remission in UPA has 
been investigated in several studies. In a Taipei cohort, Chan et al. found that the ARR in 
those with complete clinical success were significantly higher than those without (21). Sawka 
et al. also reported an association of a higher preoperative ARR with hypertension remission 
in UPA, but the association was only found in univariate analysis (23). Though there were 
significant differences in the ARR between the training and validation cohorts, our results 
demonstrated that the ARR in those with complete clinical success was significantly higher 
than those without in the training and validation cohorts alike. A multivariate analysis also 
confirmed the ARR as a strong independent predictor of hypertension remission in UPA. We 
speculate that UPA patients with a higher ARR at the time of screening were more likely to 
have severe disease (such as higher blood pressure and hypokalemia), and were therefore 
diagnosed and treated in a timely manner, enabling better clinical outcomes after surgery.  
In the present study, by incorporating the selected components of ARS and PASO score 
in addition to the ARR into the NBPS, we developed a useful clinical outcome prediction tool 
for UPA patients. Further analyses reveal that the AUC of the NBPS is higher than that of 
ARS and PASO in the training cohort, and not significantly different from PASO score in the 
validation cohort. We think the NBPS provide additional value to the PASO score in some 
ways. On the one hand, the NBPS was developed in an Asian cohort, and its AUC is 
significantly higher than PASO [0.85 (0.79-0.91) vs. 0.75 (0.67-0.82), p=0.012]. The 
validation of NBPS was conducted in a Caucasian cohort, and the AUC was similar to PASO. 
It should be noted that the characteristics of UPA (i.e. KCNJ5 mutation rate and tumor size) 
were different between Caucasian and Asian patients (37). Our analyses indicated that the 
NBPS is applicable to both Caucasian and Asian patients, with a superior performance in the 
Asian population. On the other hand, the use of less variables (4 in NBPS vs. 6 in PASO) and 
visualized scoring of the nomogram ensures that the NBPS is user-friendly.  
 Utsumi T et al. also used a nomogram to estimate hypertension remission in UPA by 
incorporating age, female sex, duration of hypertension and number of anti-hypertensive 
drugs (20). Our newly developed nomogram, after multi-ethnic training and validation, 
excluded parameters of age and the number of antihypertensive drug and additionally 
included ARR and target organ damage. Furthermore, we converted our nomogram into a 
more user-friendly score which should facilitate its wide clinical use. A comparison of our 
NBPS with the nomogram established by the Japanese team (21) revealed that the AUC of the 
NBPS performed better than the nomogram in the training cohort, although no significant 
difference was found in the validation cohort. Taken together, our results indicated that the 
newly developed NBPS offers an improvement over the previously published nomogram. 
The rate of complete clinical success differed between the training and validation cohorts, 
being much higher in the training cohort (64.7% vs. 34.5%). The difference could partially be 
explained by ethnic differences. According to our unpublished data, the somatic mutation rate 
of KCNJ5 in UPA patients in the training cohort is 76.7%, which is much higher than reported 
35% in Caucasian population (37). It is reported that UPA patients with KCNJ5 mutation has 
a higher probability of complete clinical success after adrenal surgery (38). The shorter 
duration of hypertension, higher prevalence of female patients and younger age in the training 
cohort could also explain the higher clinical remission rate.     
Our study has several strengths. Firstly, we comprehensively evaluated clinical and 
biochemical predictors of hypertension remission in UPA and all the parameters enrolled in 
the NBPS were subjected by stepwise selection. Secondly, the NBPS was developed and 
validated in different ethnic cohorts, with a very low overfitting bias. Furthermore, the current 
study excluded UPA patients with partial or absent biochemical success, as the lack of 
complete biochemical success (largely due to wrong judgment of lateralization or 
incompletely excised aldosterone producing tissues) would confound the main outcome. Thus, 
eliminating those patients may increases the reproducibility of our results. A potential 
limitation of the NBPS is the inability to differentiate patients with partial clinical success 
from those with absent clinical success. In addition, not all UPA patients in hypertension 
referral centers underwent echocardiography and microalbuminuria measurement, and this 
may be a limiting factor with the current nomogram. However, it is feasible for the majority 
of PA referral centers to pursue these investigations and fully utilize our NBPS.  
 
Conclusions 
In conclusion, we found the ARR to be a robust predictor of hypertension remission in 
UPA and established a nomogram-based preoperative score (NBPS) for the prediction of 
clinical outcomes following unilateral adrenalectomy for UPA patients in a large international 
multi-ethnic cohort. The NBPS could accurately predict hypertension remission for UPA 
patients, especially in the Asian population. Patients with a higher NBPS preoperatively are 
more likely to achieve complete resolution of their hypertension after unilateral 
adrenalectomy. In contrast, patients with a lower NBPS were more likely to experience 
ongoing hypertension and should be closely monitored following surgery with a low threshold 
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Figure 1. Flow chart. 
Figure 2. Nomogram for preoperative estimation of complete clinical success in UPA 
patients and predictive performance. 
A, Nomogram to estimate complete clinical success in UPA patients. To use the nomogram, 
find the position of each variable on the corresponding axis, draw a line to the points axis for 
the number of points, add the points from all of the variables, and draw a line from the total 
points axis to determine the possibility of complete clinical success at the lower line of the 
nomogram. B, Validation of the predictive performance of the nomogram in estimating 
complete clinical success in the training cohort (n = 150) by calibrating with 1000 bootstrap 
samples to decrease the overfit bias. C, Validation of the predictive performance of the 
nomogram in estimating the possibility of complete clinical success in the validation cohort (n 
= 165) by calibrating with 1000 bootstrap samples to decrease the overfit bias. ARR: 
aldosterone to renin ratio; HT: hypertension; TOD: target organ damage; C index: 
concordance index; ROC: receiver operating characteristic curve.  
Figure 3. Comparison of NBPS with ARS and PASO score for preoperative estimation of 
hypertension remission in UPA patients in the training cohort (A) and the validation cohort 
(B). 
ROC curve analysis was used to compare NBPS with ARS and PASO score for the estimation 
of hypertension remission in the training cohort (A) and the validation cohort (B). The AUC is 
indicated. ROC curve, receiver operating characteristic curve; NBPS, nomogram-based 
preoperative score; ARS, aldosteronoma resolution score; PASO, primary aldosteronism 
surgical outcome; AUC, the area under the ROC curve. 
Table 1. Preoperative clinical and biochemical characteristics of UPA patients in the 
training cohort. 
 Complete Clinical 
Success(n=97) 
Partial + Absent Clinical 
Success(n=53) 
P Value 
Age (years) 43.6±12.8 48.9±10.6 0.011 
Sex (M/F) 21/76 (78.4%) 30/23 (43.4%) <0.001 
Duration of hypertension (years) 3.0 (1.0,8.0) 8.0 (3.0,13.5) 0.001 
Familial history of hypertension 
(Yes/No) 
50/47 (51.5%) 27/26 (50.9%) 1.000 
History of hypokalemia (Yes/No) 83/14 (85.6%) 45/8 (84.9%) 1.000 
BMI (kg/m2) 22.7±2.7 24.8±3.5 <0.001 
SBP (mmHg) 153.4±17.6 160.7±17.4 0.016 
DBP (mmHg) 95.2±13.0 98.0±13.8 0.219 
TC (mmol/L) 4.0±0.8 3.9±0.8 0.914 
TG (mmol/L) 1.2±1.5 1.3±0.6 0.775 
Serum K+(mmol/L) 3.0±0.6 3.1±0.5 0.217 
PAC (pg/ml) 349.0 (248.5, 547.0) 314.0 (218.5, 488.5) 0.237 
ARR (pg.ml-1/mIU.l-1) 293.5 (95.8, 487.1) 89.8 (43.1, 195.4) <0.001 
PAC post-SIT (pg/ml) 288.0 (180.5, 465.0) 208.0 (133.0, 308.0) 0.013 
DDD of anti-hypertensive 
medication 
1.8±1.0 2.1±1.0 0.117 
Target organ damage (Yes/No) 55/42 (56.7%) 46/7 (86.8%) <0.001 
Left Ventricular Hypertrophy 
(Yes/No) 
40.2% 77.4% <0.001 
Microalbuminuria (Yes/No) 47.9% 57.1% 0.483 
Medical history of diabetes 
(Yes/No) 
8/89 (8.2%) 15/38 (28.3%) 0.002 
Size of largest nodule at imaging 
(mm) 
13.9±4.7 14.0±5.4 0.921 
Data were expressed as mean ± SD, median (interquartile range) and proportion (%), 
proportions indicate females, presence of familial history of hypertension, presence of 
hypokalemia, presence of diabetes and presence of target organ damage. HT, hypertension; 
BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; TC, total 
cholesterol; TG, triglyceride;  Serum K+, concentration of serum potassium; PAC, plasma 
aldosterone concentration; ARR, aldosterone to renin ratio; SIT, saline infusion test; DDD, 
defined daily dose.  
 
Table 2. Univariate logistic regression analysis of predictors of hypertension remission 
in UPA patients based on preoperative data in the training cohort. 
Variable OR (95% CI) P Value 
Age (years) 0.964 (0.937-0.992) 0.012 
Female sex 4.720 (2.282-9.766) <0.001 
Duration of hypertension (years) 0.938 (0.891-0.986) 0.012 
BMI (kg/m2) 0.794 (0.705-0.895) <0.001 
SBP (mmHg) 0.977 (0.958-0.996) 0.018 
ARR (pg.ml-1/mIU.l-1) 1.788 (1.328-2.407) <0.001 
PAC post-SIT(Pg/ml) 1.723 (1.154-2.574) 0.008 
DDD of anti-hypertensive medication 0.779 (0.569-1.066) 0.118 
Absence of target organ damage 0.199 (0.082-0.486) <0.001 
Absence of medical history of diabetes 0.228 (0.089-0.582) 0.002 
Size of largest nodule at imaging (mm) 0.997 (0.932-1.066) 0.921 
Data were expressed as OR (95% CI). HT, hypertension; BMI, body mass index; SBP, 
systolic blood pressure; PAC, plasma aldosterone concentration; ARR, aldosterone to renin 
ratio; SIT, saline infusion test; DDD, defined daily dose. 
 
 
Table 3. Stepwise selection (forward) of predictors of hypertension remission in UPA 
patients.  
Position in model Variable OR (95% CI) P Value 
First Female sex 5.374 (2.257-12.792) <0.001 
Second ARR 2.183 (1.503-3.169) <0.001 
Third Duration of hypertension  0.910 (0.854-0.970) 0.004 
Fourth Absence of target organ 
damage 
0.278 (0.099-0.783) 0.015 















Table 4. Nomogram-based preoperative score: 4 variable model. 
Variables Category Points 








Sex Male 0 
Female 3.5 
Target organ damage Yes 0 
No 2.5 










Table 5. Comparing NBPS with ARS and PASO score for the preoperative estimation of hypertension remission in UPA patients in the training and 1 
the validation cohorts. 2 
 
Variable  
Value (95% CI) 
Training cohort Validation cohort 
Predictive model NBPS ARS PASO score NBPS ARS PASO score 
Cutoff score ≥11.5 ≥4 ≥16 ≥11.5 ≥4 ≥16 
AUC 0.853 (0.786-0.905) 0.745 (0.667-0.812) 0.747 (0.670-0.815) 0.830 (0.764-0.884) 0.745 (0.672-0.810) 0.825 (0.758-0.880) 
Sensitivity% 85.6 (77.0-91.9) 72.1 (62.1-80.8) 71.1 (61.0-79.9) 68.4 (54.8-80.1) 40.4 (27.6-54.2) 70.1 (56.6-81.6) 
Specificity% 71.7 (57.7-83.2) 71.7 (57.7-83.2) 66.0 (51.7-78.5) 78.7 (69.8-86.0) 92.6 (85.9-96.7) 83.3 (74.9-89.8) 
Data were expressed as value (95% CI). NBPS, nomogram-based preoperative score; ARS, aldosteronoma resolution score; PASO, primary aldosteronism 3 
surgical outcome; AUC, the area under the receiver operating characteristic curve.4 
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